Business
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
SAN FRANCISCO, May 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, May 29, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will webcast an analyst and investor conference call on Friday, June 5, 2020 at 11:00 a.m. EDT during EULAR 2020. The event will follow Thursday's virtual poster presentation of the data from a Phase 1b multiple ascending dose study of NKTR-358, a first-in-class investigational regulatory T cell stimulator, in patients with systemic lupus erythematosus. \nAnalyst Call Details\nDate and Time: Friday, June 5, 2020 at 11:00 a.m. Eastern Daylight Time \nDial- in: (877) 881-2183 (toll-free) or (970) 315-0453 (access code 1170058) \nInvestors and analysts can also view slides and listen to the live audio webcast of the presentation at https://edge.media-server.com/mmc/p/aaf3wx35. The event will also be available for replay for two weeks on the company's website, www.nektar.com. \nPoster Presentation Details\nThe virtual poster presentation will be made available on-demand via the EULAR 2020 E-Congress site and on Nektar's website beginning on Thursday, June 4, 2020 through the duration of the conference. Additional details are as follows: \nSession Title: Adaptive immunity (T cells and B cells) in rheumatic diseasesAbstract Title: \"NKTR-358, a Novel IL-2 Conjugate, Stimulates High Levels of Regulatory T cells in Patients with Systemic Lupus Erythematosus\" Abstract: THU0054\nAbout NKTR-358 (LY3471851*)\nAutoimmune and inflammatory diseases cause the immune system to mistakenly attack and damage healthy cells in a person's body. A failure of the body's self-tolerance mechanisms enables the formation of the pathogenic T lymphocytes that conduct this attack. NKTR-358 is a potential first-in-class resolution therapeutic that may address this underlying immune system imbalance in people with different autoimmune and inflammatory conditions. It targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, NKTR-358 may act to bring the immune system back into balance. Nektar entered into a strategic collaboration with Lilly in 2017 to develop and commercialize NKTR-358.\nNKTR-358 is being developed as a self-administered injection for a number of autoimmune and inflammatory diseases.\nAbout Nektar \nNektar Therapeutics i...